



RealRate

PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



RealRate

Ventyx Biosciences Inc. Rank 66 of 466

The relative strengths and weaknesses of Ventyx Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ventyx Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Ventyx Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 183% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	263,020
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,283
Liabilities, Non-Current	0
Other Assets	28,208
Other Compr. Net Income	-58
Other Expenses	0
Other Liabilities	0
Other Net Income	-16,599
Other Revenues	0
Property and Equipment	254
Research and Development	58,481
Selling, General and Administrative Expense	8,666

Output Variable	Value in 1000 USD
Assets	291,482
Liabilities	12,283
Expenses	67,147
Revenues	0
Stockholders Equity	279,199
Net Income	-83,746
Comprehensive Net Income	-83,775
Economic Capital Ratio	261%

